KalVista Announces Positive Interim Data for EKTERLY® Trial

Pharmaceutical company reports promising results for hereditary angioedema treatment in pediatric patients.

Mar. 30, 2026 at 12:25pm

Got story updates? Submit your updates here. ›

KalVista Pharmaceuticals, a biopharmaceutical company focused on developing novel oral therapies for hereditary angioedema (HAE), has announced positive interim results from its Phase 3 KONFIDENT-KID clinical trial evaluating EKTERLY® (sebetralstat) for the treatment of HAE attacks in pediatric patients.

Why it matters

The KONFIDENT-KID trial is an important step in expanding treatment options for children and adolescents living with HAE, a rare and potentially life-threatening genetic disorder characterized by recurrent swelling episodes. Positive interim data suggests EKTERLY could provide a new oral medication to help manage HAE attacks in younger patients.

The details

The KONFIDENT-KID trial is evaluating the efficacy, safety, and pharmacokinetics of EKTERLY in pediatric patients aged 6 to 17 years with HAE. The interim analysis showed EKTERLY met the primary endpoint of time to beginning of symptom relief, with a median time of 0.5 hours. The treatment was also well-tolerated, with a safety profile consistent with previous studies in adults.

  • The KONFIDENT-KID trial is currently ongoing.
  • KalVista announced the positive interim results on March 30, 2026.

The players

KalVista Pharmaceuticals

A biopharmaceutical company focused on developing novel oral therapies for hereditary angioedema (HAE).

EKTERLY® (sebetralstat)

An investigational oral therapy being evaluated by KalVista for the treatment of HAE attacks.

Got photos? Submit your photos here. ›

What they’re saying

“These positive interim results from the KONFIDENT-KID trial are an important milestone in our efforts to bring a new oral treatment option to pediatric patients living with this debilitating condition.”

— Andrew Crockett, Chief Executive Officer of KalVista Pharmaceuticals

What’s next

KalVista plans to continue the KONFIDENT-KID trial and submit the full data for regulatory review upon completion.

The takeaway

The promising interim results for EKTERLY in the pediatric KONFIDENT-KID trial represent progress in expanding treatment options for children and adolescents with hereditary angioedema, a rare and serious genetic disorder.